Qiagen N.V. (QGEN) Shares are Up 1%

Qiagen N.V. (QGEN) : Traders are bullish on Qiagen N.V. (QGEN) as it has outperformed the S&P 500 by a wide margin of 22.41% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.95%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 1% in the last 1 week, and is up 23.67% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 9.91% and the 50-Day Moving Average is 18.91%. Qiagen N.V. (NASDAQ:QGEN): stock turned positive on Friday. Though the stock opened at $27.07, the bulls momentum made the stock top out at $27.25 level for the day. The stock recorded a low of $26.91 and closed the trading day at $27.22, in the green by 1.76%. The total traded volume for the day was 877,078. The stock had closed at $26.75 in the previous days trading.


The company Insiders own 9% of Qiagen N.V. shares according to the proxy statements. Institutional Investors own 56.94% of Qiagen N.V. shares. Also, Equity analysts at the Brokerage firm HSBC upgrades its rating on Qiagen N.V. (NASDAQ:QGEN). The rating major has initiated the coverage with buy rating on the shares. Earlier, the shares were rated a Hold by the brokerage firm. The rating by the firm was issued on August 1, 2016.

QIAGEN N.V. (QIAGEN) is a Netherlands-based holding company. The Company and its subsidiaries are engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Sample to Insight solutions are composed of sample and assay technologies, bioinformatics and automation systems. Sample to Insight molecular technologies are applicable across a range of applications and customer classes through more than 500 core consumable products, as well as instruments that automate the use of these products for sample preparation, analysis and interpretation. The Companys bioinformatics solutions connect laboratory workflows and process amounts of genomic data, enabling scientists or clinicians to interpret results and decide on further action.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.